Guyer B, Smith D R, Chalk R
Department of Population and Family Health Services, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland, USA.
Am J Prev Med. 2000 Oct;19(3 Suppl):4-12. doi: 10.1016/s0749-3797(00)00212-9.
Federal, state, and private-sector investments in vaccine purchases and immunization programs are lagging behind emerging opportunities to reduce the risks of vaccine-preventable disease. Although federal assistance to the states for immunization programs and data collection efforts rapidly expanded in the early part of the 1990s, significant cutbacks have occurred in the last 5 years that have reduced the size of state grant awards by more than 50% from their highest point. During this same period, the vaccine delivery system for children and adults has become more complex and fragmented. This combination of new challenges and reduced resources has led to instability in the public health infrastructure that supports the U. S. immunization system. Many states have reduced the scale of their immunization programs and currently lack adequate strength in areas such as data collection among at-risk populations, strategic planning, program coordination, and assessment of immunization status in communities that are served by multiple health care providers. If unmet immunization needs are not identified and addressed, states will have difficulty in achieving the national goal of 90% coverage by the year 2010 for completion of the childhood immunization series for young children. Furthermore, state and national coverage rates, which reached record levels for vaccines in widespread use (79%, 1998), can be expected to decline and preventable disease outbreaks may occur as a result, particularly among persons who are vulnerable to vaccine-preventable disease because of their underimmunization status. The Institute of Medicine (IOM) Committee on Immunization Finance Policies and Practices has therefore concluded that a renewal and strengthening of the federal and state immunization partnership is necessary. The goal of this renewed partnership is to prevent infectious disease; to monitor, sustain, and improve vaccine coverage rates for child and adult populations within more numerous and increasingly diversified health care settings; and to respond to vaccine-safety concerns. To achieve this renewal, states require a consistent strategy, additional funds, and a multiyear finance plan that can help expedite the delivery of new vaccines; strengthen the immunization assessment, assurance, and policy development functions in each state; and adapt childhood immunization programs to serve the needs of new age groups (especially adults with chronic diseases) in different health care environments. The IOM committee recommends that federal and state governments adopt a national finance strategy that would allocate $1.5 billion in federal and state resources over the first 5 years to strengthen the infrastructure for child and adult immunization-an annual increase of $175 million over current spending levels. These resources would consist of $200 million per year in state infrastructure grants awarded by the Centers for Disease Control and Prevention (the Section 317 program) and an additional $100 million per year in increased state contributions. The committee also recommends that the Congress replace the current discretionary Section 317 grants with a formula approach for state immunization grant awards to improve the targeting and stability of federal immunization grants. The formula should provide a base level of support to all states, as well as additional amounts related to each state's need, capacity, and performance. The committee further recommends that Congress introduce a state match requirement for the receipt of increased federal funds to help strengthen and stabilize the infrastructure that supports long-term public health assessment, assurance, and policy development efforts. (ABSTRACT TRUNCATED)
联邦、州和私营部门在疫苗采购和免疫计划方面的投资,落后于降低疫苗可预防疾病风险的新机遇。尽管20世纪90年代初联邦政府对各州免疫计划和数据收集工作的援助迅速增加,但在过去5年中出现了大幅削减,州政府拨款规模比最高点减少了50%以上。同一时期,儿童和成人疫苗配送系统变得更加复杂和分散。新挑战与资源减少的这种结合,导致了支持美国免疫系统的公共卫生基础设施不稳定。许多州缩小了免疫计划规模,目前在高危人群数据收集、战略规划、计划协调以及由多个医疗服务提供者服务的社区免疫状况评估等领域缺乏足够力量。如果未满足的免疫需求得不到识别和解决,各州将难以实现到2010年幼儿完成儿童免疫接种系列覆盖率达到90%的国家目标。此外,广泛使用疫苗的州和全国覆盖率在1998年达到创纪录水平(79%),预计将会下降,可能会导致可预防疾病爆发,特别是在因免疫不足而易患疫苗可预防疾病的人群中。因此,医学研究所(IOM)免疫融资政策与实践委员会得出结论,联邦和州免疫伙伴关系需要更新和加强。这种新伙伴关系的目标是预防传染病;在更多且日益多样化的医疗环境中监测、维持和提高儿童及成人的疫苗覆盖率;并应对疫苗安全问题。为实现这种更新,各州需要一个一致的战略、额外资金以及一个多年融资计划,以帮助加快新疫苗的配送;加强各州的免疫评估、保障和政策制定职能;并使儿童免疫计划适应不同医疗环境中新时代群体(特别是患有慢性病的成年人)的需求。IOM委员会建议联邦和州政府采用一项国家融资战略,在头5年分配15亿美元的联邦和州资源,以加强儿童和成人免疫基础设施——比当前支出水平每年增加1.75亿美元。这些资源将包括疾病控制和预防中心每年提供2亿美元的州基础设施拨款(第317计划)以及每年额外增加1亿美元的州政府出资。委员会还建议国会用一种公式化方法取代当前的第317节自由裁量拨款,用于州免疫拨款,以提高联邦免疫拨款的针对性和稳定性。该公式应为所有州提供基本支持水平,以及与每个州的需求、能力和绩效相关联的额外金额。委员会还进一步建议国会对获得增加的联邦资金引入州配套要求,以帮助加强和稳定支持长期公共卫生评估、保障和政策制定工作的基础设施。(摘要截选)